Canadian Agency for Drugs and Technologies in Health. (2014). Tocilizumab (Actemra, intravenous): For the treatment of signs and symptoms of active polyarticular juvenile idiopathic arthritis in patients two years of age and older who have responded inadequately to previous therapy with disease-modifying antirheumatic drugs and systemic corticosteroids. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health.
Chicago Style CitationCanadian Agency for Drugs and Technologies in Health. Tocilizumab (Actemra, Intravenous): For the Treatment of Signs and Symptoms of Active Polyarticular Juvenile Idiopathic Arthritis in Patients Two Years of Age and Older Who Have Responded Inadequately to Previous Therapy With Disease-modifying Antirheumatic Drugs and Systemic Corticosteroids. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2014.
MLA CitationCanadian Agency for Drugs and Technologies in Health. Tocilizumab (Actemra, Intravenous): For the Treatment of Signs and Symptoms of Active Polyarticular Juvenile Idiopathic Arthritis in Patients Two Years of Age and Older Who Have Responded Inadequately to Previous Therapy With Disease-modifying Antirheumatic Drugs and Systemic Corticosteroids. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2014.